INSULIN GLARGINE MARKET ANALYSIS

Key Developments

• In March 2023, Sanofi, a pharmaceutical and healthcare company, stated that it will reduce the list price of Lantus (insulin glargine injection) 100 Units/mL, its most commonly prescribed insulin in the U.S., by 78%. The company will also set a USD 35 out-of-pocket cost cap for Lantus for all patients with commercial insurance, demonstrating its long-standing commitment to providing affordable access to medicines.
• In July 2021, Biocon Biologics Ltd., a biopharmaceutical company and Viatris Inc., a global pharmaceutical company announced that Semglee (insulin glargine-yfgn injectable) had been approved by the United States Food and Drug Administration (FDA) as the first interchangeable biosimilar under the 351(k) regulatory pathway.
• In August 2020, Mylan N.V. (acquired by Viatris Inc.) and Biocon Biologics India Ltd., a subsidiary of Biocon Ltd., announced the U.S. launch of Semglee (insulin glargine injection) in vial and pre-filled pen presentations, which is approved to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.